Establishment Labs Holdings (ESTA) Lifts Outlook Following Q3 Results But Does Valuation Still Fit

Establishment Labs Holdings (ESTA) drew fresh attention on 29 October 2026 after lifting its full year 2026 revenue outlook to more than US$274 million and releasing third quarter results showing higher sales and a smaller net loss.

Despite the improved outlook, Establishment Labs Holdings shares closed at US$64.42 on 5 November. The 1-day and 7-day share price returns were down 3.76% and 5.83% respectively, while the 3-year total shareholder return of 182.79% contrasts with a weaker recent trend and suggests earlier momentum has cooled.

Scan how Establishment Labs Holdings compares with other healthcare stocks showing improving fundamentals using our hand-picked list of solid balance sheet and fundamentals (24 results).

Establishment Labs Holdings now trades at a sizeable discount to both analyst targets and one intrinsic value estimate, even after stronger guidance and slimmer losses. Is the market prudence on this medical device group still warranted?

Most Popular Narrative: 24% Undervalued

On the most followed view, Establishment Labs Holdings carries a fair value of about $85.08, which sits above the recent $64.42 close and leans heavily on how current growth eventually turns into earnings and cash.

The main requirement is that Establishment Labs Holdings converts strong U.S. growth, minimally invasive adoption, global account expansion and higher-margin mix into sustained profitability and resilient cash generation, despite ongoing GAAP net losses and mixed gross margin drivers.

The numbers imply the Establishment Labs Holdings share price reflects cautious expectations. Current revenue guidance, minimally invasive growth and early free cash flow do not yet fully offset perceived risks around profitability, competitive pressures and shareholder selling.

See why 1 investors see Establishment Labs Holdings as 24% undervalued.

Result: Fair Value of $85.08 (UNDERVALUED)

Still, if Establishment Labs Holdings extends recent free cash flow and continues increasing the higher margin U.S. and minimally invasive mix, this cautious narrative could be challenged.

Find out about the key risks to this Establishment Labs Holdings narrative.

Another View: What Multiples Say About Establishment Labs Holdings

The fair value narrative presents Establishment Labs Holdings as undervalued, yet the price tag tells a different story. The stock trades at a P/S ratio of 7.3x. That is well above the US Medical Equipment industry average of 2.9x and a peer average of 2.1x, and it also sits higher than an estimated fair ratio of 4.9x that the market could move toward over time. For investors, that kind of gap can mean paying a higher price today even if future cash flows look appealing, so the key question is whether the growth and profitability path justifies that richer starting point.

To see how this pricing gap is unpacked through earnings multiples and revenue expectations, and where the numbers could settle over time, take a look at our valuation breakdown with the See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

Curious whether the cautious tone around Establishment Labs Holdings really matches the data in front of you today? Act quickly, stress test the assumptions, and see what investors are optimistic about by going through the 3 key rewards.

Looking for more investment ideas beyond Establishment Labs Holdings?

Do not stop with one ticker. Broaden your watchlist with fresh opportunities so you are not relying on a single story to shape your returns.

• Target faster potential growth pockets by scanning 21 high quality undiscovered gems that pair strong fundamentals with under-the-radar profiles.
• Strengthen your defense by reviewing 32 resilient stocks with low risk scores built around resilient balance sheets and lower overall risk scores.
• Pursue better value entry points by checking 42 high quality undervalued stocks that combine quality fundamentals with prices that look out of sync with the underlying business.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com